April 5, 2021 5:07pm

Highs weren’t not so high and lows were not that deep

Pre-open indication results: 7 HIT and 0 Miss

News: Chinook Therapeutics (KDNY) transacted with Van Herk Investments, a European life science investor, to create and fund a new company called Sairopa, with a pipeline focused on research and development of non-renal monoclonal antibodies generated through Aduro Biotech’s B-Select platform.

Who is defining the metrics for investors and keeping you notified of the sector and market fluctuations?  What I provide is a trusted source of share pricing intelligence

Numbers based facts speak better then opinion as I see answers in numbers that equate to facts!


The Dow closed UP +373.06 points (+1.13%); the S&P closed UP +57.98 points (+1.44%) while the Nasdaq closed UP +225.49 points (+1.67%)



Indexes closed at record highs on Monday as a strong bounce in U.S. job growth and solid data in the services sector raised expectations for a swift economic recovery from the pandemic.

  • The Institute for Supply Management’s non-manufacturing activity index jumped to a reading of 63.7 last month, the highest level in the survey’s history.


News <continued from title>: KDNY will own approximately 40% of Sairopa after the first tranche of financing from Van Herk and have one seat on Sairopa’s Board of Directors.

  • As part of the merger, KDNY also assumed Aduro’s (formerly) collaboration and license agreements with Novartis Pharmaceuticals Corporation (Novartis), Eli Lilly and Company (Lilly) and Merck Sharpe & Dohme Corp. (Merck).
  • Novartis recently notified Chinook that it has discontinued development of the final STING pathway activation program under the collaboration, and as a result, has provided notice of termination of the Novartis collaboration and license agreement.


RegMed Investors’ (RMi) pre-open: what and where will the demand for increased share pricing come from?” …  https://www.regmedinvestors.com/articles/11845    


Pre-open indication results:  7 HITs <Maintain SELL: Biostage (BSTG -$0.04 to $1.30 with 2,401 shares – what would the price be if NOT “pumped”), Cellectis SA (CLLS +$1.19), CRISPR Therapeutics (CRSP +$2.58); SELL into Strength:  Athersys (ATHX +$0.01), Editas Medicine (EDIT +$0.03), Intellia Therapeutics (NTLA +$0.17), uniQure NV (QURE +$1.67) and 0 MISS


RegMed/Stem/Cell and Gene therapy’s 35 covered equities’ Advance/Decline (A/D) lines: progressions and regressions …

  • Monday opened positive at 26/6, 2 flat and 1 acquired, stayed positive at the mid-day to 18/14, 2 flats and 1 acquired, closing positive at 24/8, 2 flats and 1 acquired;


There are clear winners and losers

Jumping with share pricing momentum: yesterday’s dogs get to bark again

  • CRISPR Therapeutics (CRSP), Ionis Pharmaceuticals (IONS), Fate Therapeutics (FATE), uniQure NV (QURE), Cellectis SA (CLLS), to name 5 of the 24 inclining of the 35 covered

Hammered in today’s market:

  • BioLife Solutions (BLFS), Applied Genetic Technologies (AGTC), Chinook Therapeutics (KDNY), Global Blood Therapeutics (GBT), Mesoblast (MESO) to name 5 of the 8 declining of the 35 covered


Key metrics:

  • Sector volume had LOW with 2 of the 24-upside having higher than the 3-month average volume with the volume of 1 of 88-downside having higher than the 3-month average volume;
  • Monday’s percentage (%) of the 24-upside were +0.07% (EDIT) to +9.44% (PGEN) while the 8-downside ranges from -0.18% (SLDB) to -4.59% (AGTC);


Monday’s (10 of 24) incline

  • CRISPR Therapeutics (CRSP +$%2.58 after Thursday’s -$2.44);
  • Ionis Pharmaceuticals (IONS +$1.79);
  • Fate Therapeutics (FATE -$1.75 after Thursday’s -$0.54);
  • uniQure NV (QURE +$1.67 after Thursday’s +$0.42);
  • Cellectis SA (CLLS +$1.19 after Thursday’s -$0.47
  • Vericel (VCEL +$1.07 after Thursday’s -$2.35);
  • bluebird bio (BLUE +$1.06 after Thursday’s -$0.11);
  • Sage Therapeutics (SAGE +$1.01 after Thursday’s +$2.03);
  • Alnylam Pharmaceuticals (ALNY +$0.84 after Thursday’s +$0.62):
  • Precision (PGEN +$0.66);

Monday’s (8 of 8) decliners:

  • BioLife Solutions (BLFS -$0.97 after Thursday’s +$0.69);
  • Applied Genetic Technologies (AGTC -$0.240;
  • Chinook Therapeutics (KDNY -$0.23 after Thursday’s -$0.04);
  • Global Blood therapeutics (GBT -$0.13 after Thursday’s +$1.87);
  • Mesoblast (MESO -$0.05);
  • Caladrius Bioscience (CLBS -$0.05 after Thursday’s -$0.03);
  • Biostage (BSTG -$0.04 after Thursday’s flat);
  • Solid Biosciences (SLDB -$0.01 after Thursday’s -$0.09);

Closing: 2 – ReNeuron (RENE.L), Bellicum Pharmaceuticals (BLCM) and 1 - Stemline Therapeutics (STML – acquired)


Sentiment and COVID-19:

  • The seven-day average of daily Covid-19 deaths in the U.S. is 797, the lowest since late October. The U.S. reported a single-day record of 4.1 million vaccinations administered on Saturday, and the seven-day average of shots given is now sitting just above 3 million doses per day.

Infection cases <Million>: never to forget …

  • Monday vaccinations: 165 M
  • Monday infections: 30.49 M cases,
  • Monday’s death rate totaled 553,681 <Johns Hopkins University>



The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Monday, the IBB closed up +0.43% and XBI closed up +1.17%

The CBOE Volatility Index (VVIX: INDEX) tracked:

  • Monday was up +0.60 points or +3.46% at 17.03

Upside volume: low

  • Monday: 2 out of the 24-upside had higher than the 3-month average volume;

Downside volume: low

  • Monday: 1 out of the 8-downside had higher than the 3-month average volume;

Percentage (%) movement/range statistics: % and pricing drop

  • Monday’s percentage (%) of the 24-upside were +0.07% (EDIT) to +9.44% (PGEN) while the 8-downside ranges from -0.18% (SLDB) to -4.59% (AGTC);


April, the beginning of Q2/21:

Monday (4/5) closed positive with 24 advancers, 8 decliners, 2 flat and 1 acquired

Thursday (4/1) closed positive with 19 advancers, 13 decliners, 2 flat and 1 acquired


The BOTTOM LINE: Thursday’s I wrote, “The question will be, are sector investors ready for the Monday open and potential DRIFT of share pricing?

As I had stated, “It is hard to keep up with a volatile sector … the past couple months have been marked by choppy trading, especially heading into some of the final sessions of Q1.”

I’m STILL a “beware or the cautious man” whose focus has always been “warning analysis” … earnings’ season is NOT over … my advice, trim and skim any new highs if one can!”


Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.